Structural progression of amyloid-β Arctic mutant aggregation in cells revealed by multiparametric imaging

Received for publication, June 18, 2018, and in revised form, November 16, 2018. Published, Papers in Press, November 30, 2018, DOI 10.1074/jbc.RA118.004511

Meng Lu1, Neil Williamson1, 2, Ajay Mishra1, Claire H. Michel5, Clemens F. Kaminski1, 3, and Alan Tunnacliffe4

From the 1Cambridge Infinitus Research Centre, Department of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge CB3 0AS, United Kingdom and 2Department of Chemical Engineering and Biotechnology, University of Cambridge, West Cambridge Site, Philippa Fawcett Drive, Cambridge CB3 0AS, United Kingdom

Edited by Ursula Jakob

The 42-amino-acid β-amyloid (Aβ42) is a critical causative agent in the pathology of Alzheimer’s disease. The hereditary Arctic mutation of Aβ42 (E22G) leads to increased intracellular accumulation of β-amyloid in early-onset Alzheimer’s disease. However, it remains largely unknown how the Arctic mutant variant leads to aggressive protein aggregation and increased intracellular toxicity. Here, we constructed stable cell lines expressing fluorescent-tagged mutant Aβ42 to study the aggregation kinetics of the Arctic Aβ42 mutant peptide and its heterogeneous structural forms. Arctic-mutant peptides assemble and form fibrils at a much faster rate than WT peptides. We identified five categories of intracellular aggregate—oligomers, single fibrils, fibril bundles, clusters, and aggresomes—that underlie the heterogeneity of these Aβ42 aggregates and represent the progression of Aβ42 aggregation within the cell. Fluorescence-lifetime imaging (FLIM) and 3D structural illumination microscopy (SIM) showed that all aggregate species displayed highly compact structures with strong affinity between individual fibrils. We also found that aggregates formed by Arctic mutant Aβ42 were more resistant to intracellular degradation than their WT counterparts. Our findings uncover the structural basis of the progression of Arctic mutant Aβ42 aggregation in the cell.

Amyloid-β (Aβ) peptide is a critical causative constituent of the pathology of Alzheimer’s disease (AD) and is known to assemble in multiple configurations that are associated with different physiological or pathological effects. Aβ plaques are typically found outside the cell, but considerable recent evidence suggests that intracellular Aβ accumulation also has pathogenic relevance. Aβ peptides, most commonly 40 or 42 residues in length, are derived by proteolytic cleavage from amyloid precursor protein (APP), which not only localizes to the plasma membrane but is also found in the trans-Golgi network and multivesicular bodies as well as lysosomal and mitochondrial membranes. This provides a substantial source for the production of intracellular aggregation-prone peptide Aβ42 (10–12). It has been shown that in tissues derived from human brain, Aβ42 oligomerization initiates within cells rather than in the extracellular space (13), which may occur by the interaction of Aβ42 with lipid bilayers and lipid rafts (14, 15). In addition, cellular uptake of aggregation-prone peptides via endocytosis also leads to rapid intracellular aggregation (16, 17). This is further supported by a genome-wide study, which revealed that phosphatidylinositol-binding clathrin assembly protein (PICALM) is associated with AD (18, 19), highlighting the significance of endocytic pathways in disease development.

The intracellular aggregation of Aβ42 is an early event in the progression of the neuropathological phenotype, preceding the accumulation of extracellular Aβ42 plaques (20). Furthermore, intracellular Aβ42 impairs synaptic transmission (21), triggers mitochondrial defects (22), and leads to neuronal death. Aβ42 released from dying cells can contribute to extracellular deposits of β-amyloid as the disease progresses (23, 24). Therefore, the study of intracellular Aβ42 accumulation and aggregation is clearly of significance in understanding the development of AD.

Genetic studies of AD have revealed several mutations that aggravate the pathological effects of Aβ42. Among these, the Arctic mutation (APP E693G; Aβ42 E22G) facilitates amyloidosis by early accumulation of intracellular Aβ42 aggregates and a rapid onset of plaque deposition (26). This mutant form of Aβ42 is primarily processed at intracellular locations and forms aggregates inside the cell (27), but there is little information about the structural development or heterogeneity of these aggregates in live cell models. Therefore, an examination of the various states of Arctic mutant aggregation should provide significant insights into the understanding of intracellular amyloidogenesis. In the present study, we constructed inducible, stable, and single-copy cell lines expressing the Arctic mutant form of Aβ42 fused to the fluorescein reporter protein.
mCherry and carried out direct, in-cell observation of Aβ42 aggregation kinetics using FLIM (16) and super-resolution imaging (28–30). We identified five categories of intracellular aggregate—oligomers, single fibrils, fibril bundles, clusters, and aggresomes—that underline the heterogeneity of Aβ42 aggregates and represent the progression of Aβ42 aggregation within the cell. We also found that Arctic mutant aggregates form more rapidly and to a far greater extent in cells than WT aggregates and are inefficiently degraded.

Results

Aβ42 Arctic mutant in cell model displays a fast and aggressive aggregation phenotype

We constructed single-copy, stable cell lines in Flp-In T-REx293 cells with a cytomegalovirus promoter driving mCherry, mCherry-Aβ42(WT), or mCherry-Aβ42(E22G) expression (Fig. S1). Characterization by wide-field fluorescence microscopy showed prominent expression of the reporter proteins in these cell lines (Fig. 1, A–C). However, there was a marked difference among them with respect to the amount of protein aggregation. After a week of induction by tetracycline, mCherry was homogeneously distributed in cells (Fig. 1A), whereas mCherry-Aβ42 and its Arctic mutant formed aggregates inside cells (Fig. 1, B and C). Cells expressing the Arctic mutant Aβ42 displayed aggressive aggregation of the fusion protein with very few or no coexisting soluble fragments, indicating that most of the expressed protein is recruited into aggregates (Fig. 1C). Such aggressive aggregation was not observed in the mCherry-Aβ42(WT) cell line. In a time course experiment, visible mCherry-Aβ42(E22G) aggregates began to accumulate 24 h after gene induction and within 3 days were present in most cells. However, in the mCherry-Aβ42(WT)–expressing line, cells containing microscopically visible aggregates became apparent more slowly and by the end of the time course were only present in ~20% of the cell population (Fig. 1D). Therefore, our stable cell lines seem to mimic, albeit on a different timescale, the different assembly and aggregation properties of WT and Arctic mutant forms of Aβ42 in the respective forms of AD.

FLIM reveals different conformation states of in-cell Aβ42 species

To characterize the nature and dynamics of Arctic mutant Aβ42 assembly in cells, we used FLIM (31) to monitor the conversion of soluble protein fragments into amyloid fibrils. In our previous study, a decrease in fluorescence lifetime of a linked fluorophore was correlated with the development of β-sheet–rich amyloid structures (3, 30). In the current study, we first investigated different states of aggregated species by measuring fluorescence decay times of an associated reporter protein, mCherry. After 48 h of gene expression, the fluorescence lifetime of most of the mCherry-Aβ42(E22G) protein within the cell varied little throughout the cytosol, indicating a relatively homogeneous population of Aβ42 species within cells (Fig. 2A). Where aggregates were clearly visible, however, a lower fluorescence lifetime was observed (Fig. 2, A and B), consistent with the conversion of soluble species or loose fibrils to more compacted structures (32). To correlate the fluorescence lifetime with the underlying amyloid structure, we next imaged the same cells by SIM (Fig. 2C). In agreement with the fluorescence lifetime results, we showed that the cytosol contained primarily soluble protein, confirming that Aβ42 species were either in the soluble state or associated with a single large perinuclear aggregate, which are the large, and thus visible by confocal microscopy, fibrils that also display the low fluorescence lifetime. The higher resolution of SIM demonstrated this large aggregate to be composed of multiple fibrils.

Structural progression of Aβ42 Arctic mutant aggregates

The structural heterogeneity of the Arctic mutant aggregates suggested by FLIM and 2D SIM (Fig. 2) was next examined using 3D SIM, which can reveal morphological and structural details of aggregated protein species (4). The projection view of
3D SIM was reconstructed from a series of 2D SIM sectioning by Fiji. Fig. 3A shows representative fibrillary structures of intracellular Arctic mutant proteins at different stages of maturation. 2D SIM images and the projection view of 3D reconstructions show that, within 24 h of gene induction, Arctic mutant monomers nucleated to form single fibrils of ~100 nm in diameter and up to ~2 μm in length (Fig. 3A, day 1). As more fibrils formed in the cell, they started to assemble into loose clusters in which some fibrils were aligned with each other and apparently cross-linked but also with many gaps in the structure (Fig. 3A, day 2). The continued accumulation of fibrils gradually led to the formation of bundles, ~5 μm in diameter, consisting of multiple linear fibrils aligned in a similar orientation (Fig. 3A, day 3). Although there were still gaps between fibrils, as shown in the 2D section slice, the projection view of its 3D reconstruction showed a dense structure, suggesting the compaction of multiple layers of fibrils. These compact structures were widely observed throughout cells after 3 days of gene induction. By day 6, the fibril assemblies had matured further and showed a very different morphology: the fibril clusters were no longer largely aligned but displayed multiple, tangled branches oriented in various directions. Next, we quantified the size distribution of Arctic mutant aggregates over the 6 days of the experiment by analyzing the 2D SIM images (Fig. 3B). On day 1, ~90% of the amyloid aggregates appeared to have an area of less than 0.02 μm², which is of the order expected for oligomers. Fibrils are greater than 0.02 μm² in size, whereas fibril bundles and clusters exceed 0.1 μm². As the experiment continued, there was a progressive drop in the proportion of oligomers in the overall population from ~90% (day 1) to less than 40% (day 6), probably reflecting the assembly of oligomeric species into fibrils, fibril bundles, and larger clusters. Thus, fibrils and higher-order assemblies derived from them become the predominant species as the amyloid structures mature.

We further compared the intracellular size distribution of aggregate species of the Aβ42 Arctic mutant with two other aggregation-prone proteins, mCherry-Aβ42(WT) and polyglutamine-containing huntingtin (HDQ72) tagged with GFP (Fig. 3C) (33). Six days after induction, the Arctic mutant had the lowest level of oligomeric species (i.e. 40%; see above) and the majority of its aggregates in the form of fibrils and related structures, showing it to be the most aggressively aggregation-prone of the three proteins. In comparison, ~60% of mCherry-Aβ42(WT) aggregates and ~70% of HDQ72-EGFP aggregates had an area of less than 0.02 μm², i.e. were in the form of oligomeric species. This demonstrates that the nature of the aggre-
Figure 3. Structural progression of intracellular Arctic mutant aggregates. A, 3D-SIM demonstrates representative Arctic mutant fibrils and fibril bundles formed inside cells at different times after tetracycline induction. Upper series of panels, 2D sectioning slice of the aggregates; lower series of panels, projected view from a 3D rendering of the above. Scale bar, 1 μm. B, size distribution profile of aggregates at different time points. Aggregates from at least three images of each time point were analyzed. y axis, proportion; x axis, aggregate size (μm²). C, morphology and size comparison of aggregates formed by three different aggregation-prone proteins: mCherry-Aβ42(E22G), mCherry-Aβ42(WT), and HDQ72-EGFP. Aggregates from at least three images of each cell line were analyzed. Upper panel, sectioning slice of aggregates by SIM. Lower panel, size distribution profile of aggregates at the same time point (6 days after gene induction).
Structural progression of amyloid-β Arctic mutant

gation-prone protein, even a difference of one amino acid, can dramatically affect its aggregation properties, specifically in terms of dynamic assembly and structural organization. This highlights the importance of assessing aggregation-prone proteins individually rather than assuming that all such proteins follow the same pattern of aggregation and supramolecular assembly.

Heterogeneous state of Arctic mutant aggregates inside the cell

We next applied 3D SIM to a more detailed investigation of the different types of mCherry-Aβ42(E22G) aggregate in cells at day 7 postinduction. Because gene expression was continuous throughout this period, the whole range of aggregate species, including oligomers, single fibrils, fibril bundles, fibril clusters, and aggresomes, was present and widely distributed throughout the cytosol in essentially all cells (Fig. 4A, left and middle panels) in which the aggregate species were much more abundant compared with cells at day 2 postinduction (Fig. 2). Compared with 2D section slices (Fig. 4A, left panel), which show only a single layer of the fibrillar structure, full 3D reconstructions (Fig. 4A, middle panels) revealed the high density of the aggregate species, mostly fibrils, in this Arctic Aβ42 mutant–expressing cell. This demonstrates the ability of 3D SIM to provide comprehensive details of volumetric structures in cells. The zoomed-in regions in Fig. 4A show the heterogeneity of aggregate structures (Video S1 for image 1 and Video S2 for image 3), including oligomers (image 3, yellow arrows), single fibrils (image 3, green arrows), fibril bundles (image 3, blue arrows), and a compact fibril cluster (image 4) composed of tangled fibrillar fragments in various orientations.

The mature state of protein aggregation in these cells is characterized by the presence of a perinuclear aggresome, which is formed when the protein degradation system is overwhelmed (34). Aggresomes are highly compact structures comprising branched and tangled fibrils positioned at or near the centrosome (35) (Fig. 4B and Video S3). A typical example of an mCherry-Aβ42(E22G) aggresome is shown in the top left panel of Fig. 4B with z-stack section slices at the depths indicated in the lower left panels of Fig. 4B. These sections demonstrate the internal organization of tangled fibrils in the aggresome, which is further reconstructed as a 3D structure in the right panel of Fig. 4B. This amorphous morphology is consistent with the random assembly of fibrillar structures, either by diffusion or active transport, rather than a more ordered assembly of monomeric or oligomeric species at a nucleation site.

Inefficient degradation of Aβ42 Arctic mutant aggregates

The aggressive accumulation of Arctic mutant aggregates in cells could result from either its rapid assembly into fibrils, its resistance to degradation, or a combination of both. The Aβ42 Arctic mutant has been reported to greatly promote the formation of protofibrils/oligomers (25) and can generate fibrils at much lower concentrations and higher rates than WT Aβ42 in vitro (36). In the WT peptide, Glu-22 destabilizes the oligomer structure by electrostatic repulsion between adjacent Glu-22 side chains. In silico modeling revealed that substituting glycine at this position replaces glutamic acid with an uncharged residue, resulting in higher oligomer stability (37). The lack of a side chain in glycine may also provide greater conformational flexibility and avoid steric interference among Aβ42 peptides (38).

Furthermore, glycine is more hydrophobic and α-helix–destabilizing than glutamic acid (39) and thus virtually eliminates the α-helix propensity in the region adjacent to Gly-22, as shown in molecular dynamics simulations (40). Our results are consistent with the above analyses in the literature and a much faster rate of aggregation of the Arctic mutant than WT Aβ42 in living cells.

To test the second premise, that Arctic mutant aggregates are more resistant to degradation than WT, we investigated whether pre-existing mCherry-Aβ42(E22G) aggregates (present after 1 week of induction) can be efficiently degraded when no new Arctic mutant protein is produced. When mCherry-Aβ42(WT) or mCherry-Aβ42(E22G) gene expression was switched off in the respective inducible cell lines, we observed a progressive decrease in the proportion of cells containing aggregates of both types (Fig. 5A). After 4 days, the mCherry-Aβ42(WT) cells had degraded almost all of their aggregates; however, ~50% of the population of Arctic mutant–expressing cells still contained visible aggregates, mainly accumulated in aggresomes, showing that these aggregates are highly resistant to intracellular degradation. To further address this issue, we used 3D SIM to analyze aggregate structures remaining in cells 4 days after mCherry-Aβ42(E22G) gene expression was switched off. As shown in Fig. 5B, a representative cell still contained a compact aggresome, whereas separate fibrillar structures were no longer observed, indicating that these smaller species had been cleared from the cytosol. This large aggregate consists of a highly dense core and a less compact peripheral region containing discernible individual species, as shown in the z-section slice (Fig. 5B, right panel). A large, dense structure of this kind is likely to be more resistant to processing by the ubiquitin-proteasome system and autophagy than looser, smaller assemblies of aggregated protein (41, 42).

Because the Arctic mutant cells generate more aggregates than WT Aβ42 cells, the apparent resistance to degradation of the former aggregates could simply be due to the degradation machinery becoming overwhelmed. To assess this, we incubated mCherry-Aβ42(E22G) cells with tetracycline for 24 h, which resulted in the formation of a limited number of small aggregates and single fibrils (Fig. 5C, day 1). Then we removed the inducer and analyzed the aggregates in these samples over the following 4 days (Fig. 5C, days 2–5). We found that the fibrils and small aggregates formed within 24 h persist throughout this period. This is consistent with Arctic mutant aggregates being intrinsically highly resistant to degradation. Thus, the results of Fig. 5A are unlikely to be due to the degradation machinery being overwhelmed or to a special property of aggregates within aggresomes.

Discussion

The emergence and proliferation of Aβ42 plaques in AD brains could be due to several factors: 1) an increase in production of Aβ42 peptides, 2) compromised cellular degradation systems, and/or 3) the rigid structure and stability of Aβ42 amyloid. In this study, we investigated the structural progres-
Figure 4. Super-resolved structures of intracellular Arctic mutant aggregates. A, left, a section slice showing an Arctic mutant–expressing cell containing numerous fibrillary fragments, which are in different states of aggregation in the cytosol. The nucleus was stained with Hoechst 33342 (blue and outlined with a blue dashed line). The yellow dashed line shows the outline of the cell. The zoomed regions are numbered 1–4. Middle and right panels are the projected views from 3D rendering. Image 3 shows oligomers (yellow arrows), single fibrils (green arrows), and fibril bundles (blue arrows). Image 4 shows a fibril cluster. B, high-resolution SIM images of an aggresome. The nucleus was stained with Hoechst 33342 (blue). Left panel, z-stack sectioning slice of an aggresome that contains tightly connected fibrillary fragments. Right panel, projected view from 3D rendering of the images from the left panel.
Structural progression of amyloid-β Arctic mutant

sion of aggregates of the Aβ42 Arctic-mutant peptide in living cells and obtained insights into its fast aggregation and resistance to protein clearance. To do this, we introduced a cell model that expresses the Aβ42 Arctic-mutant peptide, tagged by the fluorescent protein mCherry, which mimics intracellular amyloid formation. Our model demonstrates that a single point mutation in Aβ42, E22G, has a dramatic effect on Aβ42 protein homeostasis, leading to rapid and aggressive amyloid fibril for-
The aggregation of Aβ42 Arctic mutant initiates from oligomerization of monomers, which then rapidly assemble to form fibrils. Multiple fibrils connect with high affinity to form bundles, clusters, and eventually aggresomes. The five phases in the structural progression of Arctic mutant aggregates are shown from left to right. Phase 1, soluble oligomers in cytosol. Phase 2, linear fibrils ranging from 500 nm to 2 μm in length, representing amyloid building blocks and the most universal form of intracellular aggregates. Phase 3, fibril bundles consisting of multiple fibrils aligned in a similar orientation. Phase 4, multiple fibrils assembled as a tightly bound cluster. Phase 5, a large number of fibrillary fragments that form highly compacted aggresomes, which are resistant to degradation.

In the development of aggregates, we found that fibrils first aligned in the same orientation to form fibril bundles and then assembled in a random way to form clusters and aggresomes as the intracellular fibril concentration increases. We demonstrated that the single residue change in the mutant Aβ42 peptide leads to significant differences in amyloid progression and structures, which are resistant to intracellular degradation. How these different amyloid states lead to intracellular toxicity needs to be fully addressed in the future; this model provides a platform for studying the effect of intracellular amyloid on the function of various cellular compartments. In addition, because this model demonstrates various stages of protein aggregation, it can also be used for the screening of antiaggregation compounds.

**Experimental procedures**

**Cells**

Sequence of plasmids used for stable cell line construction are given in the supporting information. Mammalian Flp-In T-REx293 cells were grown in T75 or T25 flasks or 6-well plates by incubation at 37 °C in a 5% CO₂ atmosphere (35). Complete medium consists of 90% Dulbecco’s modified Eagle’s medium, 10% fetal bovine serum, and 2 mM L-glutamine; antibiotics were used as appropriate (35). Cells were passaged on reaching 80–90% confluence (approximately every 3–4 days) and kept in logarithmic phase growth. Routine cell counting and viability assays were carried out using a hemocytometer and trypan blue. Transfections were performed on cells at 80% confluence. Stable cell line construction has been described previously (32).

**Microscopy**

The protocol of cell fixation for imaging was as described previously (32). After induction for various times, cells were fixed, and images were recorded with an OMX V3 super-resolution microscope (35).
Structural progression of amyloid-β Arctic mutant

Confocal microscopy was performed as described previously (35). FLIM experiments were carried out using custom-built time-correlated single photon counting as described before (16). FLIM images were analyzed by FLIMfit (31). Imaging of section slices was acquired from the OMX, and 3D reconstruction from multiple section slices was performed by Fiji Volume Viewer, which produced 3D projection views of the reconstruction.


Acknowledgment—We thank Dr. Tatsuya Yoshimi for help with the molecular cloning.

References


Structural progression of amyloid-β Arctic mutant aggregation in cells revealed by multiparametric imaging
Meng Lu, Neil Williamson, Ajay Mishra, Claire H. Michel, Clemens F. Kaminski, Alan Tunncliffe and Gabriele S. Kaminski Schierle
doi: 10.1074/jbc.RA118.004511 originally published online November 30, 2018

Access the most updated version of this article at doi: 10.1074/jbc.RA118.004511

Alerts:
- When this article is cited
- When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts

This article cites 44 references, 13 of which can be accessed free at http://www.jbc.org/content/294/5/1478.full.html#ref-list-1